Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV artesunate plus ACT versus IV quinine plus ACT for severe malaria with pharmacokinetic evaluation of artemether-lumefantrine and dihydroartemisinin-piperaquine
PACTR201110000321348Completed
- Sponsor
- Infectious Diseases Institute
- Start
- Oct 2011
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of artesunate, quinine, artemether, lumefantrine, dihydroartemisinin and 1 more in malaria (2 arms), sponsored by Infectious Diseases Institute. Primary endpoint: Treatment failure unadjusted by genotyping. Started Oct 2011; status: completed.
02
Drugs
artesunatequinineartemetherlumefantrinedihydroartemisinin
03
Conditions
malaria
Beyond the preview
Go deeper on PACTR201110000321348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201110000321348.